Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line

Submitted by admin on August 13, 2018 - 11:39am
Source: 
Endpoints
News Tags: 
Regeneron
Eylea
Novartis
RTH258
wet age-related macular degeneration
FDA
Headline: 
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
snippet: 

An aggressive Regeneron $REGN has run into a roadblock in its quest to get out ahead of a potential Eylea rival from Novartis.

Do Not Allow Advertisers to Use My Personal information